Clinical trials: Piperacillin-tazobactam
Pneumonia
Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia
Primary Objective: The primary objective of the study is to demonstrate the non-inferiority in clinical efficacy at the test of cure (TOC) visit planned 5-7 days after treatment completion of levofloxacin 750 mg once daily (od)…
- Trial name
- NCT00253955
- Testing
- Levofloxacin, Piperacillin/Tazobactam
- Where
- 17 sites in Austria, Belgium and 15 more
- Volunteers
- 460 people
- Sponsor
- Sanofi
Healthy
A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants
The main purpose of this study is to evaluate the effect of intravenous (IV) infusions of piperacillin/tazobactam on the pharmacokinetics (PK) of JNJ-63549109 after a single oral dose of lumicitabine in healthy adult participants.
- Trial name
- NCT03441529
- Testing
- Lumicitabine, Piperacillin/Tazobactam
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Abscess, Wound Infection
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
Patients, who are considered suitable by their physicians to take part in this research, will have a physical examination (including an Electrocardiogram (ECG)), blood and urine samples taken, as well as a sample of the…
- Conditions
- Abscess, Wound Infection, Diabetic Foot, Ulcer
- Trial name
- NCT00402727
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
- Where
- 123 sites in Austria, Belgium and 18 more
- Volunteers
- 813 people
- Sponsor
- Bayer
Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia
Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)
This study will evaluate the efficacy and safety of a FDC of imipenem/cilastatin (IMI) and relebactam (REL) [IMI/REL, MK-7655A] compared to piperacillin/tazobactam (PIP/TAZ) in the treatment of adults diagnosed with…
- Trial name
- NCT03583333
- Testing
- IMI/REL FDC, PIP/TAZ FDC, Linezolid
- Where
- 68 sites in Brazil, China and 6 more
- Volunteers
- 274 people
- Sponsor
- Merck Sharp & Dohme LLC
Urinary Infections
Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections
- Trial name
- NCT00195286
- Testing
- piperacillin/tazobactam
- Where
- 27 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hematologic Neoplasms
Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma
To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in…
- Trial name
- NCT00044759
- Testing
- Piperacillin/Tazobactam (Tazocin)
- Where
- 36 sites in United States, Canada
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Complicated Intra-Abdominal Infections
Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)
This study is designed to compare the efficacy of ertapenem and piperacillin/tazobactam with respect to the clinical response in baseline microbiologically evaluable patients; and to evaluate the tolerability and safety of…
- Trial name
- NCT00389987
- Testing
- MK0826, /Duration of Treatment : 8 Weeks, Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks
- Volunteers
- 300 people
- Sponsor
- Merck Sharp & Dohme LLC
Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia
A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
The purpose of this study is to determine the efficacy, safety, tolerability, and pharmacokinetics (PK) of meropenem-vaborbactam compared to piperacillin/tazobactam for 7 to 14 days in the treatment of hospitalized adults who…
- Conditions
- Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia
- Trial name
- TANGOIII (NCT03006679)
- Testing
- Meropenem-Vaborbactam, Piperacillin/Tazobactam
- Sponsor
- Melinta Therapeutics, Inc.
Urinary Tract Infection Complicated, Acute Pyelonephritis
Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
- Trial name
- NCT02166476
- Testing
- Meropenem-Vaborbactam, Piperacillin-Tazobactam, Levofloxacin
- Where
- 77 sites in United States, Belarus and 15 more
- Volunteers
- 550 people
- Sponsor
- Melinta Therapeutics, Inc.
Ventilator-Associated Pneumonia (VAP)
Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia
This is a Phase 3, multicenter, prospective, randomized, open-label, study to compare the safety and efficacy of intravenous (IV) ceftolozane/tazobactam with that of IV piperacillin/tazobactam in the treatment of…
- Trial name
- NCT01853982
- Testing
- Ceftolozane/Tazobactam, Piperacillin/Tazobactam
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 4 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bacterial Pneumonia
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
This study aims to compare treatment with a fixed-dose combination (FDC) of imipenem/relebactam/cilastatin (IMI/REL) with a FDC of piperacillin/tazobactam (PIP/TAZ) in participants with hospital-acquired or ventilator-associated…
- Trial name
- RESTORE-IMI 2 (NCT02493764)
- Testing
- Imipenem, Relebactam, Cilastatin
- Volunteers
- 537 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematological Malignancy, Leukemia
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for fever in neutropenic patients.
- Conditions
- Hematological Malignancy, Leukemia, Myelodysplasia, Lymphoma
- Trial name
- NCT00195533
- Testing
- piperacillin-tazobactam, glycopeptide
- Where
- 12 sites in Spain
- Volunteers
- 801 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Urinary Tract Infections
Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections
Multi-center, randomized, double-blind, non-inferiority study of cefepime 2 g/AAI101 500 mg combination compared to piperacillin 4 g/tazobactam 500 mg in a population of adult patients with cUTI or AP.
- Trial name
- NCT03687255
- Testing
- cefepime/AAI101 combination, Piperacillin/tazobactam
- Where
- 24 sites in United States, Argentina and 17 more
- Volunteers
- 1,043 people
- Sponsor
- Allecra
Diabetes Mellitus, Diabetic Foot
Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections
Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.
- Trial name
- NCT00044746
- Testing
- Piperacillin/Tazobactam
- Volunteers
- 314 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Foot Infections in Diabetic Patients
Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034)
This study will compare the efficacy, safety and tolerability of intravenous ertapenem versus another intravenous antibiotic in the treatment of moderate to severe diabetic foot infections.
- Trial name
- NCT00229112
- Testing
- MK0826, ertapenem sodium / Duration of Treatment - 24 weeks, Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
Appendicitis
A Study Comparing Safety and Efficacy of Levofloxacin and Metronidazole Versus Piperacillin/Tazobactam in Treating Complicated Appendicitis
The purpose of this study is to compare the efficacy and safety of two treatment regimens in treating patients with complicated appendicitis.
- Trial name
- NCT00236912
- Testing
- levofloxacin; metronidazole
- Volunteers
- 139 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bacterial Infections
Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection
A Phase IV, multicenter study of hospitalized patients with complicated intra-abdominal infection.
- Trial name
- NCT00044928
- Testing
- Piperacillin/Tazobactam
- Volunteers
- 262 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Urinary Tract Infection Symptomatic, Acute Pyelonephritis
Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections
The purpose of the study is to demonstrate the safety and efficacy of ZTI-01 (IV fosfomycin) as non-inferior to piperacillin/tazobactam in overall success (clinical cure and microbiologic eradication) for the treatment of…
- Conditions
- Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
- Trial name
- ZEUS (NCT02753946)
- Testing
- ZTI-01, Piperacillin-tazobactam
- Where
- 68 sites in United States, Belarus and 14 more
- Volunteers
- 465 people
- Sponsor
- Nabriva Therapeutics AG
Gram-Positive Bacterial Infections, Escherichia Coli Infections
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in…
- Conditions
- Gram-Positive Bacterial Infections, Escherichia Coli Infections, Klebsiella Infections
- Trial name
- NCT00167999
- Testing
- piperacillin-tazobactam
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infection; Diabetic Foot
Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)
This study compared ertapenem sodium to piperacillin/tazobactam sodium for the treatment of moderate to severe diabetic foot infections.
- Trial name
- NCT01370616
- Testing
- Ertapenem sodium, Piperacillin/tazobactam sodium, Amoxicillin/clavulunate potassium
- Volunteers
- 565 people
- Sponsor
- Merck Sharp & Dohme LLC